Sun Pharma is down 6% in a month amid weak Q1 results, US FDA scrutiny, and tariff fears. SEBI RA Deepak Pal says long-term investors may accumulate near ₹1,500-1,550 via SIP. But short-term traders should stay cautious-technical charts show no reversal yet. RSI is weak, MACD negative, and sentiment remains bearish on Stocktwits.